** Shares in Formycon XETR:FYB rise 3% in early Frankfurt trade after the German biopharmaceutical company said that Valorum Biologics will commercialise its biosimilar to Eylea in the U.S. and Canada** Formycon will participate in the mid-single-digit to low-double-digit percentage range in all pa…Read More
German biopharma Formycon gains after US, Canada Eylea biosimilar deal
By TradingView
